IMUNOHISTOCHEMISTRY MICROSATELLITE INSTABILITY PANEL Test
Are you looking for information about the IMUNOHISTOCHEMISTRY MICROSATELLITE INSTABILITY PANEL test? Look no further! DNA Labs UAE offers this diagnostic tool to assess the status of microsatellite instability in tumor tissues. Read on to learn more about the test cost, symptoms, diagnosis, and more.
Test Name: IMUNOHISTOCHEMISTRY MICROSATELLITE INSTABILITY PANEL Test
Test Components:
- MLH-1
- MSH-2
- MSH-6
- PMS-2
Price: 2020.0 AED
Sample Condition:
Submit tumor tissue in 10% Formal-saline or Formalin fixed paraffin embedded block. Ship at room temperature. Provide a copy of the Histopathology report, Site of biopsy, and Clinical history.
Report Delivery:
- Sample: Daily by 6 pm
- Report Block: 5 days
- Tissue Biopsy: 5 days
- Tissue large complex: 7 days
Method: Immunohistochemistry
Test Type: Cancer
Doctor: Oncologist, Pathologist
Test Department:
Pre Test Information:
Provide a copy of the Histopathology report, Site of biopsy, and Clinical history.
Test Details:
The Immunohistochemistry Microsatellite Instability (MSI) Panel test is a diagnostic tool used to assess the status of microsatellite instability in tumor tissues. Microsatellites are repetitive DNA sequences that are prone to mutations in tumors with defective DNA mismatch repair (MMR) systems.
This test involves staining tumor tissue samples with specific antibodies to detect the presence or absence of key proteins involved in DNA MMR. The MSI panel typically includes antibodies against four MMR proteins: MLH1, MSH2, MSH6, and PMS2. These proteins form complexes that play a crucial role in repairing DNA mismatches and maintaining genomic stability.
Loss of expression of any of these proteins is indicative of a defective MMR system and is associated with microsatellite instability. The test involves immunohistochemical staining of tumor tissue sections with these antibodies. If the staining is absent or reduced in any of the proteins, it suggests a potential MMR deficiency and microsatellite instability.
The results of this test can help guide treatment decisions, as MSI-high tumors are more likely to respond to immune checkpoint inhibitors. It is important to note that this test is typically performed on tumor tissue samples obtained from biopsies or surgical resections. It is not a blood test and cannot be used to diagnose microsatellite instability in other body fluids or non-tumor tissues.
Overall, the Immunohistochemistry Microsatellite Instability Panel test is a valuable tool in the evaluation of tumors for microsatellite instability and can provide important information for treatment decisions in certain cancers.
Test Name | IMUNOHISTOCHEMISTRY MICROSATELLITE INSTABILITY PANEL Test |
---|---|
Components | *MLH-1*MSH-2*MSH-6*PMS-2 |
Price | 2020.0 AED |
Sample Condition | Submit tumor tissue in 10% Formal-saline OR Formalin fixed paraffin embedded block. Ship at room temperature. Provide a copy of the Histopathology report, Site of biopsy and Clinical history. |
Report Delivery | Sample Daily by 6 pm; Report Block: 5 days Tissue Biopsy: 5 days Tissue large complex : 7 days |
Method | Immunohistochemistry |
Test type | Cancer |
Doctor | Oncologist, Pathologist |
Test Department: | |
Pre Test Information | Provide a copy of the Histopathology report, Site of biopsy and Clinical history. |
Test Details | The Immunohistochemistry Microsatellite Instability (MSI) Panel test is a diagnostic tool used to assess the status of microsatellite instability in tumor tissues. Microsatellites are repetitive DNA sequences that are prone to mutations in tumors with defective DNA mismatch repair (MMR) systems. This test involves staining tumor tissue samples with specific antibodies to detect the presence or absence of key proteins involved in DNA MMR. The MSI panel typically includes antibodies against four MMR proteins: MLH1, MSH2, MSH6, and PMS2. These proteins form complexes that play a crucial role in repairing DNA mismatches and maintaining genomic stability. Loss of expression of any of these proteins is indicative of a defective MMR system and is associated with microsatellite instability. The test involves immunohistochemical staining of tumor tissue sections with these antibodies. If the staining is absent or reduced in any of the proteins, it suggests a potential MMR deficiency and microsatellite instability. The results of this test can help guide treatment decisions, as MSI-high tumors are more likely to respond to immune checkpoint inhibitors. It is important to note that this test is typically performed on tumor tissue samples obtained from biopsies or surgical resections. It is not a blood test and cannot be used to diagnose microsatellite instability in other body fluids or non-tumor tissues. Overall, the Immunohistochemistry Microsatellite Instability Panel test is a valuable tool in the evaluation of tumors for microsatellite instability and can provide important information for treatment decisions in certain cancers. |